**Development and Validation of a Nomogram Based on CA125 Levels for Predicting** **Progression-free Survival in Patients with Ovarian Cancer**

Minjun He 1,3,#, Chuanbo Xie2,3,#, Jun Huang4,#, Wei Wei1,3, Yin Wang1,3,

Chunyan Lan1,3

1. Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
2. Department of Cancer Prevention, Sun Yat-sen University Cancer Center, Guangzhou, China
3. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
4. Ganzhou People’s Hospital, The Affiliated Hospital of Nanchang University,16 Mei Guan Road, Ganzhou 341000 Jiangxi, China

# Contributed equally to this work.

Corresponding author:

Chunyan Lan, MD, Associate Professor

Department of Gynecology Oncology,

Sun Yat-sen University Cancer Center,

State Key Laboratory of Oncology in South China,

Collaborative Innovation Center for Cancer Medicine,

651 Dongfeng Road East, Guangzhou 510060, Guangdong, China.

Tel: +86-20-87343870

Fax: +86-20-87343014.

Email: [lanchy@sysucc.org.cn](mailto:lanchy@sysucc.org.cn).

**Appendix 2. Point Assignment and Prognostic Score**

|  |  |
| --- | --- |
| Variables | Score |
|
| Age groups |  |
| ≤ 50 | 0 |
| ＞50 | 3 |
| FIGO stage |  |
| II | 0 |
| III | 7 |
| IV | 10 |
| Grade |  |
| Grade1 | 3 |
| Grade2 | 0 |
| Grade3 | 1 |
| Residual disease |  |
| < 1cm (Optimal debulking) | 0 |
| ≥ 1cm (Suboptimal debulking) | 9 |
| Normalization of CA125 levels after  three cycles of chemotherapy |  |
| Yes | 0 |
| No | 8 |